Ekkehard Eigendorff

749 total citations
19 papers, 416 citations indexed

About

Ekkehard Eigendorff is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Ekkehard Eigendorff has authored 19 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Genetics and 6 papers in Oncology. Recurrent topics in Ekkehard Eigendorff's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Ekkehard Eigendorff is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Myeloid Leukemia Research (4 papers). Ekkehard Eigendorff collaborates with scholars based in Germany, Switzerland and France. Ekkehard Eigendorff's co-authors include Andreas Hochhaus, Thomas Ernst, Janine M. Ziermann, Orlando Guntinas‐Lichius, Peter Schlattmann, Susanne Saußele, Rüdiger Hehlmann, Martin C. Müller, Iver Petersen and Jenny Rinke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ekkehard Eigendorff

19 papers receiving 413 citations

Peers

Ekkehard Eigendorff
Nadjat Mounedji France
G. Rosti Italy
Sadashivudu Gundeti India
R T Silver United States
Anna V. Christophoridou Greece
Lokanatha Dasappa India
P. Reinecke Germany
Konstantinos Tsionos Greece
K. Govind Babu India
Luigiana Luciano Italy
Nadjat Mounedji France
Ekkehard Eigendorff
Citations per year, relative to Ekkehard Eigendorff Ekkehard Eigendorff (= 1×) peers Nadjat Mounedji

Countries citing papers authored by Ekkehard Eigendorff

Since Specialization
Citations

This map shows the geographic impact of Ekkehard Eigendorff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ekkehard Eigendorff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ekkehard Eigendorff more than expected).

Fields of papers citing papers by Ekkehard Eigendorff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ekkehard Eigendorff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ekkehard Eigendorff. The network helps show where Ekkehard Eigendorff may publish in the future.

Co-authorship network of co-authors of Ekkehard Eigendorff

This figure shows the co-authorship network connecting the top 25 collaborators of Ekkehard Eigendorff. A scholar is included among the top collaborators of Ekkehard Eigendorff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ekkehard Eigendorff. Ekkehard Eigendorff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Schmoll, Hans‐Joachim, Lars H. Lindner, Peter Reichardt, et al.. (2020). Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma. JAMA Oncology. 7(2). 255–255. 22 indexed citations
3.
4.
Hochhaus, Andreas, Ekkehard Eigendorff, & Thomas Ernst. (2019). Chronische Myeloische Leukämie. TumorDiagnostik & Therapie. 40(1). 43–49. 2 indexed citations
5.
Hochhaus, Andreas, Ekkehard Eigendorff, & Thomas Ernst. (2018). Chronische Myeloische Leukämie. DMW - Deutsche Medizinische Wochenschrift. 143(18). 1304–1310. 2 indexed citations
6.
Wirth, Lori J., Ekkehard Eigendorff, Jaume Capdevila, et al.. (2018). Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.. Journal of Clinical Oncology. 36(15_suppl). 6024–6024. 37 indexed citations
7.
Mothes, Henning, et al.. (2017). Surgery for colorectal cancer in elderly patients: how can we improve outcome?. Journal of Cancer Research and Clinical Oncology. 143(9). 1879–1889. 13 indexed citations
8.
Padula, William V., Richard A. Larson, Stacie B. Dusetzina, et al.. (2016). Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. JNCI Journal of the National Cancer Institute. 108(7). djw003–djw003. 73 indexed citations
9.
Inhestern, Johanna, Thomas Wendt, Jens Buentzel, et al.. (2016). Role of comorbidity on outcome of head and neck cancer: a population‐based study in Thuringia, Germany. Cancer Medicine. 5(11). 3260–3271. 35 indexed citations
10.
Petersen, Iver, et al.. (2015). Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds?. Journal of Cancer Research and Clinical Oncology. 142(4). 885–893. 30 indexed citations
11.
Burchert, Andreas, Susanne Saußele, Ekkehard Eigendorff, et al.. (2015). Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 29(6). 1331–1335. 43 indexed citations
12.
Eigendorff, Ekkehard & Andreas Hochhaus. (2015). Akute Leukämien des Erwachsenen. Der Pathologe. 36(5). 503–519. 8 indexed citations
13.
Hochhaus, Andreas, Paul La Rosée, Ekkehard Eigendorff, & Thomas Ernst. (2015). Chronische myeloische Leukämie. Der Internist. 56(4). 333–343. 1 indexed citations
14.
Hochhaus, Andreas, Thomas Ernst, Ekkehard Eigendorff, & Paul La Rosée. (2015). Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients. Annals of Hematology. 94(S2). 133–140. 23 indexed citations
15.
Kreil, Sebastian, Lionel Adès, Martin Bommer, et al.. (2015). Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes. Blood. 126(23). 2812–2812. 18 indexed citations
16.
Larson, Richard A., Rena M. Conti, William V. Padula, et al.. (2014). What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. Blood. 124(21). 738–738. 9 indexed citations
17.
Schmidt, Mathias, Jenny Rinke, Vivien Schäfer, et al.. (2014). Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 28(12). 2292–2299. 88 indexed citations
18.
Sommer, Michael, Ulf Teichgräber, S. Hahnfeld, et al.. (2013). Safety and Efficacy Of Bendamustine In Patients With Aggressive Non-Hodgkin Lymphomas (NHL). Blood. 122(21). 4371–4371. 3 indexed citations
19.
Hochhaus, Andreas, Thomas Ernst, Janine M. Ziermann, Ekkehard Eigendorff, & Paul La Rosée. (2012). Chronische myeloische Leukämie. Der Onkologe. 18(12). 1105–1114. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nadjat Mounedji Breakdown of academic impact, for papers by G. Rosti Breakdown of academic impact, for papers by Sadashivudu Gundeti Breakdown of academic impact, for papers by R T Silver Breakdown of academic impact, for papers by Anna V. Christophoridou Breakdown of academic impact, for papers by Lokanatha Dasappa Breakdown of academic impact, for papers by P. Reinecke Breakdown of academic impact, for papers by Konstantinos Tsionos Breakdown of academic impact, for papers by K. Govind Babu Breakdown of academic impact, for papers by Luigiana Luciano
Rankless by CCL
2026